Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis

Dow Jones05-16

By Robb M. Stewart

Ionis Pharmaceuticals and Biogen have canned development of an investigational therapy for amyotrophic lateral sclerosis after testing showed it didn't slow the disease process.

The companies said Thursday they have decided to terminate work on the investigational antisense oligonucleotide based on topline results from their Phase 1/2 study.

The proposed treatment, BIIB105, was designed to reduce expression of ataxin-2 protein and demonstrated statistically significant cerebrospinal fluid ATXN2 protein reductions in the study.

However, the companies said over the six-month placebo-controlled period, treatment with BIIB105 didn't result in a reduction in levels of plasma neurofilament light chain, a marker of neurodegeneration and neuronal damage. BIIB105 also didn't demonstrate an impact on clinical outcome measures of function, breathing and strength.

No evidence of benefit was observed in any subgroup evaluated, Ionis and Biogen said.

They said analyses of data from the study continue to further understand the underlying disease process and effects of BIIB105, and they plan to present the data at the upcoming European Network to Cure ALS meeting in Stockholm in June.

Biogen and Ionis said they continue their long-standing commitment to developing therapies for ALS.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

May 16, 2024 08:05 ET (12:05 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2435710986?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-16 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2435710986","market":"sg","top_or_hot":-1,"title":"Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre>\n \n</pre>\n<p>\n  Ionis Pharmaceuticals and Biogen have canned development of an investigational therapy for amyotrophic lateral sclerosis after testing showed it didn't slow the disease process. \n</p>\n<p>\n  The companies said Thursday they have decided to terminate work on the investigational antisense oligonucleotide based on topline results from their Phase 1/2 study. \n</p>\n<p>\n  The proposed treatment, BIIB105, was designed to reduce expression of ataxin-2 protein and demonstrated statistically significant cerebrospinal fluid ATXN2 protein reductions in the study. \n</p>\n<p>\n  However, the companies said over the six-month placebo-controlled period, treatment with BIIB105 didn't result in a reduction in levels of plasma neurofilament light chain, a marker of neurodegeneration and neuronal damage. BIIB105 also didn't demonstrate an impact on clinical outcome measures of function, breathing and strength. \n</p>\n<p>\n  No evidence of benefit was observed in any subgroup evaluated, Ionis and Biogen said. \n</p>\n<p>\n  They said analyses of data from the study continue to further understand the underlying disease process and effects of BIIB105, and they plan to present the data at the upcoming European Network to Cure ALS meeting in Stockholm in June. \n</p>\n<p>\n  Biogen and Ionis said they continue their long-standing commitment to developing therapies for ALS. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 16, 2024 08:05 ET (12:05 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-16 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Robb M. Stewart \n\n\n \n\n\n  Ionis Pharmaceuticals and Biogen have canned development of an investigational therapy for amyotrophic lateral sclerosis after testing showed it didn't slow the disease ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2435710986","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435710986","pubTimestamp":1715861100,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Ionis Pharmaceuticals and Biogen have canned development of an investigational therapy for amyotrophic lateral sclerosis after testing showed it didn't slow the disease process.The companies said Thursday they have decided to terminate work on the investigational antisense oligonucleotide based on topline results from their Phase 1/2 study.The proposed treatment, BIIB105, was designed to reduce expression of ataxin-2 protein and demonstrated statistically significant cerebrospinal fluid ATXN2 protein reductions in the study.However, the companies said over the six-month placebo-controlled period, treatment with BIIB105 didn't result in a reduction in levels of plasma neurofilament light chain, a marker of neurodegeneration and neuronal damage. BIIB105 also didn't demonstrate an impact on clinical outcome measures of function, breathing and strength.No evidence of benefit was observed in any subgroup evaluated, Ionis and Biogen said.Biogen and Ionis said they continue their long-standin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司","BK4532":"文艺复兴科技持仓","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","BK4588":"碎股","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IONS":"Ionis Pharmaceuticals, Inc","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC"},"translate_title":"Biogen,Ionis终止BIIB105治疗肌萎缩侧索硬化的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1,"IONS":0.9},"content_text":"By Robb M. Stewart \n\n\n \n\n\n  Ionis Pharmaceuticals and Biogen have canned development of an investigational therapy for amyotrophic lateral sclerosis after testing showed it didn't slow the disease process. \n\n\n  The companies said Thursday they have decided to terminate work on the investigational antisense oligonucleotide based on topline results from their Phase 1/2 study. \n\n\n  The proposed treatment, BIIB105, was designed to reduce expression of ataxin-2 protein and demonstrated statistically significant cerebrospinal fluid ATXN2 protein reductions in the study. \n\n\n  However, the companies said over the six-month placebo-controlled period, treatment with BIIB105 didn't result in a reduction in levels of plasma neurofilament light chain, a marker of neurodegeneration and neuronal damage. BIIB105 also didn't demonstrate an impact on clinical outcome measures of function, breathing and strength. \n\n\n  No evidence of benefit was observed in any subgroup evaluated, Ionis and Biogen said. \n\n\n  They said analyses of data from the study continue to further understand the underlying disease process and effects of BIIB105, and they plan to present the data at the upcoming European Network to Cure ALS meeting in Stockholm in June. \n\n\n  Biogen and Ionis said they continue their long-standing commitment to developing therapies for ALS. \n\n\n \n\n\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2024 08:05 ET (12:05 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435710986"}